- Amgen (NasdaqGS:AMGN) released new VESALIUS-CV Phase 3 subgroup data on Repatha showing a significant reduction in first major cardiovascular events in high risk patients with diabetes.
- The results indicate that Repatha, used alongside statins or other LDL C lowering therapies, may support earlier intervention for patients without diagnosed atherosclerosis.
- These findings position Repatha as the only PCSK9 inhibitor with evidence across both primary and secondary prevention settings.
For investors watching Amgen at a share price of $348.77, this update speaks directly to the depth of its cardiovascular franchise. Over the past year the stock is up 17.2%, with a 3 year return of 58.5% and a 5 year return of 63.8%, reflecting long term value creation around its drug portfolio.
This new Repatha data could influence how clinicians think about treating high risk patients earlier. It may also shape the long term role of Amgen in cardiovascular care. Investors will likely focus on how these results translate into clinical guidelines and payer decisions and, over time, the durability of demand within Amgen's cholesterol lowering segment.
Stay updated on the most important news stories for Amgen by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Amgen.
4 things going right for Amgen that this headline doesn't cover.
Quick Assessment
- ⚖️ Price vs Analyst Target: At US$348.77, Amgen trades roughly 0.5% below the US$350.55 analyst price target, which is effectively in line with consensus.
- ✅ Simply Wall St Valuation: Simply Wall St currently views the shares as trading about 46.8% below its estimated fair value, a sizeable gap.
- ❌ Recent Momentum: The 30 day return of about 10.1% decline shows short term weakness despite the supportive Repatha data.
To decide whether it may be the right time to buy, sell or hold Amgen, you can review Simply Wall St's company report for the latest analysis of Amgen's fair value.
Key Considerations
- 📊 The new Repatha results strengthen Amgen's position in high risk cardiovascular care, which could be important given its existing cholesterol lowering portfolio.
- 📊 Watch how treatment guidelines, reimbursement decisions and prescription trends for high risk diabetic patients respond to this Phase 3 subgroup data.
- ⚠️ Simply Wall St flags that Amgen's debt is not well covered by operating cash flow, so investors may want to weigh that balance sheet risk against any Repatha upside.
Dig Deeper
For the full picture including more risks and rewards, check out the complete Amgen analysis. Alternatively, you can visit the community page for Amgen to see how other investors believe this latest news will impact the company's narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com